Skip to main content
Publications
Forsythe E, Haws RM, Argente J, Beales P, Martos-Moreno GA, Dollfus H, Chirila C, Gnanasakthy A, Buckley BC, Mallya UG, Clement K, Haqq AM. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023 Jan 16;18(1):12. doi: 10.1186/s13023-022-02602-4
Kuhnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clement K. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022 Feb 5;17(1):38. doi: 10.1186/s13023-022-02186-z
Noel E, Dussol B, Lacombe D, Bedreddine N, Fouilhoux A, Ronco P, Genevaz D, Bekri S, Hagege A, Dupuis-Simeon F, Derrien Ansquer V, Germain DP, Lidove O. Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire. Orphanet J Rare Dis. 2019 Dec 4;14(1):284. doi: 10.1186/s13023-019-1254-7
Olivieri M, Murgia N, Carsin AE, Heinrich J, Benke G, Bono R, Corsico AG, Demoly P, Forsberg B, Gislason T, Janson C, Jogi R, Leynaert B, Rovira JM, Norback D, Nowak D, Pascual S, Pin I, Probst-Hensch N, Raherison C, Sigsgaard T, Svanes C, Toren K, Urrutia I, Weyler J, Jarvis D, Zock JP, Verlato G. Effects of smoking bans on passive smoking exposure at work and at home. The European Community respiratory health survey. Indoor Air. 2019 Jul;29(4):670-9. doi: 10.1111/ina.12556
Paquin RS, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, Martin AS, Morris C, Rensch C, Ricotti V, Russo LJ, Sadosky A, Smith EC, Peay H. Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients. Orphanet J Rare Dis. 2019 May 9;14(1):102. doi: 10.1186/s13023-019-1069-6
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Panella P, Casas M, Donaire‐Gonzalez D, Garcia‐Esteban R, Robinson O, Valentín A, Gulliver J, Momas I, Nieuwenhuijsen M, Vrijheid M, Sunyer J. Ultrafine particles and black carbon personal exposures in asthmatic and non-asthmatic children at school age. Indoor Air. 2017 Sep;27(5):891-9. doi: 10.1111/ina.12382
Norback D, Zock JP, Plana E, Heinrich J, Tischer C, Jacobsen R, Sunyer J, Kunzli N, Villani S, Olivieri M, Verlato G, Soon A, Schlunssen V, Gunnbjornsdottir MI, Jarvis D. Building dampness and mould in European homes in relation to climate, building characteristics and socio-economic status: the European Community Respiratory Health Survey ECRHS II. Indoor Air. 2017 Sep;27(5):921-32. doi: 10.1111/ina.12375
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.
Casas L, Tischer C, Wouters IM, Valkonen M, Gehring U, Doekes G, Torrent M, Pekkanen J, Garcia-Esteban R, Hyvarinen A, Heinrich J, Sunyer J. Endotoxin, extracellular polysaccharides, and β(1-3)-glucan concentrations in dust and their determinants in four European birth cohorts: results from the HITEA project. Indoor Air. 2013 Jun;23(3):208-18. doi: 10.1111/ina.12017
Svanes C, Dharmage S, Sunyer J, Zock JP, Norback D, Wjst M, Henrich J, Jarvis D, de Marco R, Plana E. Long-term reliability in reporting of childhood pets by adults interviewed twice, 9 years apart. Results from the European community respiratory health survey I and II. Indoor Air. 2008 Apr;18(2):84-92.